# Starling Oncology, Inc. Revenue Beats Estimates by $1.11 Million in Q3

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/50831
Published: 2026-11-07T13:02:33.000Z
Updated: 2026-11-07T13:02:33.000Z
Section: Business

> The company posted a 14-cent GAAP loss per share and positive adjusted EBITDA of $3.4 million. Cash and cash equivalents totaled $36.9 million as of Sept. 30.

Starling Oncology, Inc. (STLN) posted third-quarter 2026 revenue of $169.8 million, beating estimates by $1.11 million. GAAP earnings per share was a 14-cent loss, missing estimates by 9 cents.

Adjusted EBITDA was positive $3.4 million, compared with a loss of $3.5 million. Cash and cash equivalents totaled $36.9 million as of Sept. 30, 2026.